Berlin-based biotech-firm Caprotec Bioanalytics said that it has entered a research agreement with Syngenta to profile the interactions of one of Syngenta's active compounds with the proteome of certain relevant plant systems.

The companies will use Caprotec's Capture Compound Mass Spectrometry technology, with Syngenta covering the research costs and providing Caprotec with success-based milestone payments. Further financial details were not disclosed.

Caprotec's CCMS technology uses capture compounds to reversibly bind target proteins on the basis of small molecule-protein interactions. The captured proteins are then pulled out and analyzed via mass spectrometry.

The deal is the second that Caprotec has announced in recent weeks for use of its CCMS technology in agri-bio research. Last month the company announced a research collaboration with Bayer CropScience using CCMS to identify and study an agrochemical target.